Therapeutic Vaccination with Dendritic Cells Loaded with Autologous HIV Type 1-Infected Apoptotic Cells

Journal of Infectious Diseases

Volumn 213, Issue 9, 2016, Pages 1400-1409

  Macatangay, Bernard J C ^a   Riddler, Sharon A ^a   Wheeler, Nicole D ^a   Spindler, Jonathan ^d   Lawani, Mariam ^a   Hong, Feiyu ^a   Buffo, Mary J ^b   Whiteside, Theresa L ^b   Kearney, Mary F ^d   Mellors, John W ^a   Rinaldo, Charles R ^c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

apoptotic cell; dendritic cell; HIV 1 therapeutic vaccine; residual viremia

Indexed keywords

ANTIVIRUS AGENT; DENDRITIC CELL VACCINE; GAG PROTEIN; POL PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ADULT; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOLYSIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INJECTION SITE PAIN; LIMIT OF DETECTION; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; T LYMPHOCYTE ACTIVATION; VACCINATION; VIRUS LOAD; AUTOTRANSPLANTATION; BIOLOGICAL THERAPY; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; DENDRITIC CELL; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; PROCEDURES; TRANSPLANTATION; VIROLOGY;

ADULT; AIDS VACCINES; APOPTOSIS; CD8-POSITIVE T-LYMPHOCYTES; CELL- AND TISSUE-BASED THERAPY; DENDRITIC CELLS; HIV INFECTIONS; HIV-1; HUMANS; TRANSPLANTATION, AUTOLOGOUS; VIRAL LOAD;

EID: 84971647396     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv582     Document Type: Article

References (30)

1. Palmer S, Maldarelli F, Wiegand A, et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A 2008; 105:3879-84.
2. Zheng L, Bosch RJ, Chan ES, et al. Predictors of residual viraemia in patients on long-term suppressive antiretroviral therapy. Antivir Ther 2013; 18:39-43.
3. Shan L, Deng K, Shroff NS, et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 2012; 36:491-501.
4. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18:767-811.
5. Huang XL, Fan Z, Borowski L, et al. Dendritic cells reveal a broad range of MHC class I epitopes for HIV-1 in persons with suppressed viral load on antiretroviral therapy. PLoS One 2010; 5:e12936.
6. Kurle S, Thakar M, Shete A, Paranjape R. In vitro sensitization of T cells with DCassociated/delivered HIV constructs can induce a polyfunctional CTL response, memory T-cell response, and virus suppression. Viral Immunol 2012; 25:45-54.
7. Subramanya S, Armant M, Salkowitz JR, et al. Enhanced induction of HIV-specific cytotoxic T lymphocytes by dendritic cell-targeted delivery of SOCS-1 siRNA. Mol Ther 2010; 18:2028-37.
8. Smith KN, Mailliard RB, Larsen BB, et al. Dendritic cells restore CD8+ T cell reactivity to autologous HIV-1. J Virol 2014; 88:9976-90.
9. Garcia F, PlanaM, Climent N, Leon A, Gatell JM, Gallart T. Dendritic cell based vaccines for HIV infection: The way ahead. Hum Vaccin Immunother 2013; 9:2445-52.
10. Garcia F, Leon A, Gatell JM, Plana M, Gallart T. Therapeutic vaccines against HIV infection. Hum Vaccin Immunother 2012; 8:569-81.
11. Garcia F, Climent N, Guardo AC, et al. A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication. Sci Transl Med 2013; 5:166ra2.
12. Connolly NC, Whiteside TL, Wilson C, Kondragunta V, Rinaldo CR, Riddler SA. Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals. Clin Vaccine Immunol 2008; 15:284-92.
13. Macatangay BJ, Szajnik ME, Whiteside TL, Riddler SA, Rinaldo CR. Regulatory T cell suppression of Gag-specific CD8T cell polyfunctional response after therapeutic vaccination of HIV-1-infected patients on ART. PLoS One 2010; 5:e9852.
14. Zhao XQ, Huang XL, Gupta P, et al. Induction of anti-human immunodeficiency virus type 1 (HIV-1) CD8(+) and CD4(+) T-cell reactivity by dendritic cells loaded with HIV-1 X4-infected apoptotic cells. J Virol 2002; 76:3007-14.
15. Whiteside TL, Piazza P, Reiter A, et al. Production of a dendritic cell-based vaccine containing inactivated autologous virus for therapy of patients with chronic human immunodeficiency virus type 1 infection. Clin Vaccine Immunol 2009; 16:233-40.
16. Cillo AR, Sobolewski MD, Bosch RJ, et al. Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A 2014; 111:7078-83.
17. Cillo AR, Vagratian D, Bedison MA, et al. Improved single-copy assays for quantification of persistent HIV-1 viremia in patients on suppressive antiretroviral therapy. J Clin Microbiol 2014; 52:3944-51.
18. Besson GJ, Lalama CM, Bosch RJ, et al. HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy. Clin Infect Dis 2014; 59:1312-21.
19. Kearney MF, Spindler J, Shao W, et al. Lack of detectable HIV-1 molecular evolution during suppressive antiretroviral therapy. PLoS Pathog 2014; 10:e1004010.
20. Riou C, BurgersWA, Mlisana K, et al. Differential impact of magnitude, polyfunctional capacity, and specificity of HIV-specific CD8+ T cell responses on HIV set point. J Virol 2014; 88:1819-24.
21. Turk G, Ghiglione Y, Falivene J, et al. Early Gag immunodominance of the HIVspecific T-cell response during acute/early infection is associated with higher CD8+ T-cell antiviral activity and correlates with preservation of the CD4+ Tcell compartment. J Virol 2013; 87:7445-62.
22. Okada H, Kalinski P, Ueda R, et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 2011; 29:330-6.
23. Carreno BM, Becker-Hapak M, Huang A, et al. IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity. J Clin Invest 2013; 123: 3383-94.
24. Rinaldo CR. Dendritic cell-based human immunodeficiency virus vaccine. J Intern Med 2009; 265:138-58.
25. Palmer S,Wiegand AP, Maldarelli F, et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 2003; 41:4531-6.
26. Maldarelli F, Palmer S, King MS, et al. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog 2007; 3:e46.
27. Riddler SA, Aga E, Bosch RJ, et al. Continued slow decay of the residual plasma viremia level in HIV-1-infected adults receiving long-term antiretroviral therapy. J Infect Dis 2016; 213:556-60.
28. Wilkin TJ, McKinnon JE, DiRienzo AG, et al. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes. J Infect Dis 2009; 199:866-71.
29. van der Sluis RM, van Montfort T, Pollakis G, et al. Dendritic cell-induced activation of latent HIV-1 provirus in actively proliferating primary T lymphocytes. PLoS Pathog 2013; 9:e1003259.
30. Norton TD, Miller EA, Bhardwaj N, Landau NR. Vpx-containing dendritic cell vaccine induces CTLs and reactivates latent HIV-1 in vitro. Gene Ther 2015; 22:227-36.